Physician profile
Vincent Gregory Johnson
NPI 1447363312
$3,373.68
in general payments reported to CMS, 2019-2025
32 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $417 · 2021: $264 · 2022: $346 · 2023: $730 · 2024: $414 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $577.93 | 2019-2025 | Proclaim |
| Boston Scientific Corporation | $426.21 | 2021-2025 | Intracept, General - Pain Management |
| Medtronic USA, INC. | $401.49 | 2019-2020 | |
| Si-Bone, INC. | $393.47 | 2019-2023 | |
| Scilex Pharmaceuticals INC. | $235.73 | 2020-2024 | Ztlido |
| Relievant Medsystems, INC. | $194.96 | 2023 | Intracept |
| Collegium Pharmaceutical, INC. | $146.92 | 2020-2024 | Xtampza, Belbuca |
| Medtronic, INC. | $105.78 | 2022-2023 | Intellis Adaptivestim |
| Nevro Corp. | $79.44 | 2019-2020 | |
| Depuy Synthes Sales INC. | $79.33 | 2019 | |
| Protega Pharmaceutials INC | $70.82 | 2024-2025 | Roxybond |
| Redhill Biopharma INC. | $68.99 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $67.87 | 2022-2023 | Seglentis |
| Bioventus LLC | $47.59 | 2022-2023 | Gelsyn-3 |
| Elutia, INC. | $41.27 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Painteq LLC | $39.39 | 2024 | Painteq |
| Biotronik Nro, INC. | $38.67 | 2025 | Prospera |
| Forte Bio-Pharma LLC | $38.57 | 2021-2023 | Prolate, Nalocet |
| Valinor Pharma, LLC | $36.96 | 2023-2024 | Movantik |
| Vertex Pharmaceuticals Incorporated | $34.86 | 2024 | |
| Averitas Pharma INC. | $30.98 | 2023 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.87 | 2019-2020 | |
| Virtus Pharmaceuticals LLC | $23.80 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $23.24 | 2024 | Kristalose |
| Ferring Pharmaceuticals INC. | $22.72 | 2023 | Euflexxa |
| Merck Sharp & Dohme LLC | $22.18 | 2023 | Belsomra |
| Ibsa Pharma INC. | $19.94 | 2021 | |
| Horizon Therapeutics Plc | $19.04 | 2021 | |
| Baudax Bio INC. | $16.35 | 2020 | |
| Daiichi Sankyo INC. | $16.11 | 2019 | |
| Pfizer INC. | $14.02 | 2019 | |
| Allergan, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.